• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
SUBSCRIBE
2 Minute Medicine
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Chronic Disease

Mindfulness-based cognitive therapy is not superior to maintenance antidepressants in preventing depression recurrence or relapse [PREVENT trial]

byStefan TrelaandMarc Succi, MD
April 23, 2015
in Chronic Disease
Reading Time: 2 mins read
Social integration may reduce suicide risk in male health professionals
Share on FacebookShare on Twitter

1. This single-blind, multicenter, randomized controlled trial found that mindfulness-based cognitive therapy with support to taper or discontinue antidepressant therapy did not significantly reduce depression relapses or recurrences within 24 months of follow-up in participants diagnosed with recurrent major depressive disorder, compared to maintenance antidepressant therapy.

2. Both treatments, however, were associated with positive outcomes in reducing rates of relapses or recurrences.

Evidence Rating Level: 1 (Excellent)      

Study Rundown: Without treatment, individuals with depression are more likely to suffer recurrences and relapses throughout their lives. In those with a history of recurrent depression, antidepressant treatment for at least two years is the current standard for preventing recurrences and relapses, however, many patients may prefer other options besides medications to treat their depression. Mindfulness-based cognitive therapy (MBCT) has been shown to reduce rates or relapse or recurrence of depression compared to placebo or standard care. This study compared MBCT with support to taper or discontinue antidepressant treatment (MBCT-TS) against maintenance antidepressants in the prevention of relapses and recurrences over 24 months.

The results showed that MBCT-TS did not significantly reduce relapses or recurrences of depression over the 24 month follow-up period, compared to maintenance antidepressant therapy. However, both treatment methods provided similar positive outcomes in reductions of rates of depression relapse or recurrence. Strengths of the study included a larger sample size and longer follow-up than previous similar studies. Limitations of the study included a lack of a control group for usual care and including participants who were open to considering both group psychosocial treatment and discontinuing antidepressant treatment, limiting applicability to those who may be considering other treatments.

Click to read the study in The Lancet

RELATED REPORTS

Artificial intelligence (AI) chatbot reduced depression, anxiety, and eating disorder risk symptoms

Selective serotonin reuptake inhibitors may reduce risk of total joint arthroplasty in osteoarthritis

Use of selective serotonin reuptake inhibitors guided by pharmacogenetic testing may improve treatment response in depression

Relevant Reading: Mindfulness-based cognitive therapy for preventing relapse in recurrent depression: a randomized dismantling trial

In-Depth [randomized controlled trial]: The PREVENT trial was a multicenter, single-blind, parallel, randomized controlled trial conducted between March 2010 and October 2011 in the UK. 424 adults aged 18 and older who were diagnosed with recurrent major depressive disorder according to DSM-IV criteria, suffered three or more major depressive episodes, and were on maintenance antidepressants were included in the study. Participants were randomized (1:1) to receive either maintenance antidepressants or 8 weeks of MBCT-TS class. Research assessors were blinded to treatment, while participants and clinicians were aware of treatment allocation. The primary outcome was time to depression relapse or recurrence within 24 months, assessed at five follow-up intervals.

189 (89%) participants in the MBCT-TS group and 194 (92%) in the antidepressant group completed the study. The results showed that MBCT-TS did not significantly reduce relapse or recurrence compared to antidepressant treatment (hazard ratio [HR] 0.89, 95% Confidence Interval [CI] 0.67-1.18, p=0.43), with similar rates of relapse in each group, with 94 (44%) participants in the MBCT-TS group compared to 100 (47%) in the antidepressant group (p=0.41).

Image: PD

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: depression
Previous Post

Using adhesive strips with dermal sutures does not improve cosmesis

Next Post

Prednisolone and pentoxifylline do not reduce mortality in alcoholic hepatitis [STOPAH trial]

RelatedReports

Artificial Intelligence

Artificial intelligence (AI) chatbot reduced depression, anxiety, and eating disorder risk symptoms

September 11, 2026
Physical therapy reduces pain in adults with knee osteoarthritis
Chronic Disease

Selective serotonin reuptake inhibitors may reduce risk of total joint arthroplasty in osteoarthritis

May 21, 2026
Children’s hospital visits for suicide ideation and attempts are increasing
Chronic Disease

Use of selective serotonin reuptake inhibitors guided by pharmacogenetic testing may improve treatment response in depression

May 13, 2026
Parents often unaware of adolescents’ suicidal thoughts
Psychiatry

Psychotherapy identified as most effective treatment for grief

February 2, 2026
Next Post
Prednisolone and pentoxifylline do not reduce mortality in alcoholic hepatitis [STOPAH trial]

Prednisolone and pentoxifylline do not reduce mortality in alcoholic hepatitis [STOPAH trial]

PD

Substance use linked with increased mortality in individuals released from prison

New chemotherapy precludes the need for radiotherapy in primary mediastinal B-cell lymphoma

Pazopanib plus paclitaxel may increase survival in platinum-resistant ovarian cancer

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

5-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • The use of neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer may reduce mortality
  • Alcohol use declines but remains above pre-pandemic levels
  • High maternal egg-peanut intake not associated with reduced infant allergy
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

5-day free trial · cancel anytime

Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free · only $4.16/month

Start 5-day free trial

Then $49.90/year. Manage renewal in your account.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.